The Takeovers Panel has agreed to hear Mayne Pharma’s latest dispute with Cosette over the US drug maker’s attempts to walk away from their $672 million merger agreement and extended the timeline for completing the deal.
Mayne Pharma has secured an extension of the deadline for securing Foreign Investment Review Board approval of its $672 million tie-up with US drug maker Cosette.
Cosette plans to appeal a ruling that rejected its bid to terminate an agreement to merge with Mayne Pharma, as the US drug company also refuses to agree to conditions needed to win Foreign Investment Review Board approval for the tie-up.
Mayne Pharma has won a dispute with US drug maker Cosette over the termination of a $672 million merger agreement, with a judge finding Mayne did not breach its continuous disclosure obligations by failing to disclose a letter from the US FDA sooner.
TaxiApps, the operator of the GoCatch rideshare app, has failed to prove that Uber engaged in an unlawful conspiracy, despite a judge finding the rideshare giant intended to harm the defunct taxi app and “surreptitiously” obtained a confidential driver list.
Mayne Pharma and US drug maker Cosette have agreed to postpone the start of trial in a case over the termination of a $672 million merger to allow for late amendments.
Mayne Pharma has denied US drug maker Cosette’s claims it breached its continuous disclosure obligations in relation to US FDA concerns about marketing for its Nextstellis contraceptive, as the drug makers spar over their $672 million merger.
A court has heard US drug maker Cosette may amend its case to accuse Adelaide’s Mayne Pharma of continuous disclosure breaches in their battle over the termination of their $672 million merger.
Mayne Pharma has said it may seek to shut out US drug maker Cosette’s expert evidence in proceedings over the purported termination of their $672 million merger.
Class action settlements leaped in value last year, with three settlements topping the $200 million mark.